Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Printed By
Senate refers S 687 to the Judiciary Committee March 2 for a period of 42 days, ending when the Senate returns from its Easter recess April 11. At that time, Judiciary must file its report, and the bill will then proceed to the Senate floor. The committee has scheduled a March 15 hearing on the product liability bill, and the Senate will recess on March 25. The Senate Commerce Committee approved S 687 on Nov. 9 ('The Pink Sheet" Nov. 15, 1993, T&G-4)
| Table |
|---|
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
